Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.44 |
| ▸ | HTR3B | O95264 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743759 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL398432 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551527 | 0.80 | PLAU (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551530 | 0.80 | PLAU (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1227408 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551549 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1227404 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL7456811 | 0.79 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5546939 | 0.78 | SLC22A2 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5546942 | 0.78 | SLC22A2 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-22 | — | — | US | claimed |
| EP-4306546-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | Daiichi Sankyo Company, Limited (JP) | 2024-01-17 | — | — | EP | claimed |
| WO-2022191313-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | 第一三共株式会社 | 2022-09-15 | — | — | WO | claimed |
| US-10870710-B2 | Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof | MEDIMMUNE LIMITED (GB) | 2020-12-22 | — | — | US | claimed |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4486753-B1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | UNIV JIANGNAN (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | ACADEMIA SINICA (TW) | 2026-01-08 | — | — | US | disclosed |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-13 | — | — | US | disclosed |
| US-20250282809-A1 | Chemical Synthesis Method for Pseudomonas aeruginosa Serotype O5 O-Antigen Oligosaccharide | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250282810-A1 | Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250276993-A1 | PSEUDO-DISACCHARIDE COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2025-09-04 | — | — | US | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070106080-A1 | Process for production of 1-aryl-5-(trifluoromethyl)-1h-tetrazoles | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070106080-A1 | Process for production of 1-aryl-5-(trifluoromethyl)-1h-tetrazoles | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004058777-A1 | TITANIUM CENTERED CATALYSTS FOR THE LIVING POLYMERIZATION OF OLEFINS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-4299831-A | 2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them | ROUSSEL UCLAF (FR) | 1981-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282810-A1 | Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides | DDOST, OGA, DAD1 | HTR3E 3214/4885HTR3B 3159/4885HTR3A 2087/4885 |
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | STT3B, ST3GAL3, HACD3 | HTR3E 1037/4885HTR3B 1372/4885HTR3A 1878/4885 |
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | FUT6, ST6GAL1, NEU2 | HTR3E 3267/4885HTR3B 2163/4885HTR3A 2778/4885 |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | PKLR, RPS17, OSTC | HTR3E 4555/4885HTR3B 4606/4885HTR3A 4816/4885 |
| US-20250276993-A1 | PSEUDO-DISACCHARIDE COMPOUNDS | HPSE, HEXD, HEXA | HTR3E 715/4885HTR3B 1705/4885HTR3A 1952/4885 |
| US-20070106080-A1 | Process for production of 1-aryl-5-(trifluoromethyl)-1h-tetrazoles | TH, NAT1, PAH | HTR3E 2442/4885HTR3B 1737/4885HTR3A 1835/4885 |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | NEU2, ST6GAL1, NEU3 | HTR3E 1496/4885HTR3B 3284/4885HTR3A 2107/4885 |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | FUT6, FUT5, ST3GAL3 | HTR3E 4034/4885HTR3B 3636/4885HTR3A 3134/4885 |
| US-20250282809-A1 | Chemical Synthesis Method for Pseudomonas aeruginosa Serotype O5 O-Antigen Oligosaccharide | FUT5, FUT6, FUCA2 | HTR3E 4835/4885HTR3B 4546/4885HTR3A 4314/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | HTR3E 2954/4885HTR3B 3100/4885HTR3A 3679/4885 |
| US-10870710-B2 | Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof | PSPH, STT3B, DDOST | HTR3E 4804/4885HTR3B 4762/4885HTR3A 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.